A novel high-throughput neutralization assay for supporting clinical evaluations of human cytomegalovirus vaccines

► We developed a neutralizing assay for measuring antiviral activity against CMV. ► This assay format is no longer relying on virus induced cytopathic effect and can be easily adapted to high throughput format. ► We demonstrated its utility to support clinical and vaccine studies.